Navigation Links
ViroPharma to Present at the Maxim Group First Annual Growth Conference
Date:9/13/2007

EXTON, Pa., Sept. 13 /PRNewswire-FirstCall/ -- ViroPharma Incorporated (Nasdaq: VPHM) today announced that Vincent Milano, vice-president, chief operating officer and chief financial officer of ViroPharma, will present at the Maxim Group First Annual Growth Conference at 2:30 P.M. ET on Thursday, September 20, 2007. The conference is being held at the Grand Hyatt in New York.

ViroPharma's presentation will be webcast live for investors through http://www.viropharma.com and available through October 4, 2007.

About ViroPharma Incorporated

ViroPharma Incorporated is a biopharmaceutical company dedicated to the development and commercialization of products that address serious diseases treated by physician specialists and in hospital settings. ViroPharma commercializes Vancocin(R), approved for oral administration for treatment of antibiotic-associated pseudomembranous colitis caused by Clostridium difficile and enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains (for prescribing information, please download the package insert at http://www.viropharma.com/docs/Vancocin_pi_2007.htm). ViroPharma currently focuses its drug development activities in viral diseases including cytomegalovirus (CMV) and hepatitis C (HCV). For more information on ViroPharma, visit the company's website at http://www.viropharma.com.


'/>"/>
SOURCE ViroPharma Incorporated
Copyright©2007 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. ViroPharma Shares Fall As FDA Moves Towards Generic Vancocin
2. Surgeons Presented Guidelines For Postoperative Atrial Fibrillation
3. Researchers Present Ways To Reduce The Risk Of Dementia
4. Researchers Present Data Regarding The Efficiency Of Herbs
5. Critically Ill Patients More At Risk Of Infection If Glucose Is Present In Their Lung Secretions
6. Ovarian Cancer Presents ‘Target Symptoms’ Six Months Before Diagnosi
7. Drug Reactions First Present Themselves In The Mouth
8. Reminiscing Into The Past Makes You Dissatisfied With The Present
9. Living In The Past Indicates Dissatisfaction With Present
10. Movies Represent Coma In A Wrong Way
11. Onchocerciasis: Presentation And Treatment
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2017)... (PRWEB) , ... May 24, 2017 , ... Dr. Alan ... surgery in New York City. He is known for his distinguished expertise and ... vascular surgery, Dr. Benvenisty holds sub-specialty training in treating renovascular disease and aortic ...
(Date:5/24/2017)... ... 24, 2017 , ... Drs. Nicholas Rallis and Chris Chondrogiannis ... 10 years as clinical instructors for the reputable Full Mouth Rehabilitation continuing education ... program, private practitioners receive cutting-edge clinical training and learn how to perform ...
(Date:5/24/2017)... , ... May 24, 2017 , ... ... Global Policy Solutions is vehemently opposed to Donald Trump’s budget, “A New Foundation ... despair that inspires fear, demonizes the poor, marginalizes underserved populations, undermines productivity, and ...
(Date:5/24/2017)... ... May 24, 2017 , ... ... tract in which the endometrial lining of the uterus spreads into the ... Patients experiencing painful intercourse, painful periods, pelvic pain, or irregular bleeding may ...
(Date:5/24/2017)... ... ... If you are thinking of a visit to San Francisco , fall is a ... time to visit. , Business Architecture Associates is pleased to offer 5 days of training ... 4-½ day package for individuals, and as 4-½ day corporate package for up to 3 ...
Breaking Medicine News(10 mins):
(Date:5/10/2017)... BURNIE, Md. , May 10, 2017 ... retention solutions for the clinical research industry, is proud ... www.CSSiEnroll.com . The new website features both enriched ... overall user experience and enhances the company,s already well-established ... the industry. "After many months of ...
(Date:5/9/2017)... JERUSALEM , May 9, 2017  Oramed ... www.oramed.com ), a clinical-stage pharmaceutical company focused on ... today that the Canadian Intellectual Property Office has ... for Oral Administration of Exenatide". The patent covers ... analog. GLP-1 is an incretin hormone ...
(Date:5/8/2017)...  Diplomat Pharmacy, Inc. (NYSE: DPLO)., has completed its ... health care service center company based in ... relationship management programs for leading pharmaceutical manufacturers and health ... WRB will join Envoy Health Management, LLC , ... biotech firms, and other service companies. Together, WRB and ...
Breaking Medicine Technology: